CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-1.39%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$345M
AUM Growth
+$21M
(+6.5%)
Cap. Flow
+$33M
Cap. Flow
% of AUM
9.58%
Top 10 Holdings %
Top 10 Hldgs %
32.78%
Holding
466
New
14
Increased
365
Reduced
39
Closed
20
Top Buys
| 1 |
Amazon
AMZN
|
$3.98M |
| 2 |
Procter & Gamble
PG
|
$3.03M |
| 3 |
Booking.com
BKNG
|
$2.86M |
| 4 |
Apple
AAPL
|
$2.77M |
| 5 |
SPDR Gold MiniShares Trust
GLDM
|
$2.63M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$3.25M |
| 2 |
TSMC
TSM
|
$3.11M |
| 3 |
Carnival Corp
CCL
|
$2.64M |
| 4 |
On Holding
ONON
|
$2.57M |
| 5 |
Advanced Micro Devices
AMD
|
$2.07M |
Sector Composition
| 1 | Technology | 38.24% |
| 2 | Consumer Discretionary | 20.57% |
| 3 | Healthcare | 19.52% |
| 4 | Communication Services | 8.19% |
| 5 | Consumer Staples | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EQRX
276
DELISTED
EQRx, Inc. Common Stock
EQRX
| $27.8K | 0.01% |
12,513
+6,125
| +96% | +$13.6K |
|
277
Day One Biopharmaceuticals
DAWN
$773M
| $27.3K | 0.01% |
2,226
+1,262
| +131% | +$15.5K |
|
278
Arvinas
ARVN
$575M
| $27K | 0.01% |
1,374
+674
| +96% | +$13.2K |
|
279
Pliant Therapeutics
PLRX
$114M
| $26.5K | 0.01% |
1,529
+754
| +97% | +$13.1K |
|
280
Ligand Pharmaceuticals
LGND
$3.25B
| $26.4K | 0.01% |
441
+215
| +95% | +$12.9K |
|
281
Relay Therapeutics
RLAY
$710M
| $26.4K | 0.01% |
3,135
+1,541
| +97% | +$13K |
|
282
Syndax Pharmaceuticals
SNDX
$1.47B
| $25.9K | 0.01% |
1,782
+880
| +98% | +$12.8K |
|
283
Replimune Group
REPL
$494M
| $25.8K | 0.01% |
1,509
+752
| +99% | +$12.9K |
|
|
RVNC
284
DELISTED
Revance Therapeutics, Inc.
RVNC
| $25.8K | 0.01% |
2,250
+1,148
| +104% | +$13.2K |
|
|
DCPH
285
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $25.8K | 0.01% |
2,026
+997
| +97% | +$12.7K |
|
286
Tango Therapeutics
TNGX
$772M
| $25.5K | 0.01% |
2,263
+1,105
| +95% | +$12.4K |
|
287
Protagonist Therapeutics
PTGX
$3.77B
| $24.6K | 0.01% |
1,473
+723
| +96% | +$12.1K |
|
288
Keros Therapeutics
KROS
$633M
| $24.2K | 0.01% |
758
+370
| +95% | +$11.8K |
|
|
AVDL
289
Avadel Pharmaceuticals
AVDL
$1.53B
| $23.7K | 0.01% |
2,298
+1,454
| +172% | +$15K |
|
290
Ardelyx
ARDX
$1.57B
| $22.8K | 0.01% |
5,592
+2,781
| +99% | +$11.3K |
|
|
VERV
291
DELISTED
Verve Therapeutics
VERV
| $21.8K | 0.01% |
1,641
+829
| +102% | +$11K |
|
292
Innoviva
INVA
$1.29B
| $21.7K | 0.01% |
1,674
+816
| +95% | +$10.6K |
|
293
Cogent Biosciences
COGT
$1.82B
| $21.3K | 0.01% |
2,189
+1,259
| +135% | +$12.3K |
|
294
ADMA Biologics
ADMA
$4.03B
| $20.6K | 0.01% |
5,764
+2,851
| +98% | +$10.2K |
|
|
INBX
295
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $20.5K | 0.01% |
1,117
+545
| +95% | +$10K |
|
296
Adaptive Biotechnologies
ADPT
$1.96B
| $20.3K | 0.01% |
3,719
+1,828
| +97% | +$9.96K |
|
297
Collegium Pharmaceutical
COLL
$1.21B
| $20.1K | 0.01% |
899
+445
| +98% | +$9.95K |
|
|
ICPT
298
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $19.9K | 0.01% |
1,071
+524
| +96% | +$9.72K |
|
299
ImmunityBio
IBRX
$2.27B
| $19.8K | 0.01% |
11,702
+5,987
| +105% | +$10.1K |
|
300
Kymera Therapeutics
KYMR
$3.11B
| $19.8K | 0.01% |
1,421
+696
| +96% | +$9.67K |
|